Institut Bordet - Retour à la page d'accueil
en
I want to donate to research

Nathalie Meuleman

Department : Hematology
Speciality : Head of Department
 
nathalie.meuleman [at] hubruxelles.be

Publications

Potential of Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Natural Nanocarriers: Concise Review.

Authors : Draguet F, Bouland C, Dubois N, Bron D, Meuleman N, Stamatopoulos B, Lagneaux L
Year : 2023
Journal : Pharmaceutics

Recommendations on the management of multiple myeloma in 2020.

Authors : Vekemans MC, Doyen C, Caers J, Wu K, Kentos A, Mineur P, Michaux L, Delforge M, Meuleman N
Year : 2022
Journal : Acta Clin Belg

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.

Authors : Bobin A, Kyheng M, Guidez S, Gruchet-Merouze C, Richez V, Duhamel A, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Perrot A, Roussel M, Jaccard A, Petillon MO, Belhadj-Merzoug K, Chretien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Moreau P, Avet-Loiseau H, Hulin C, Facon T, Leleu X
Year : 2022
Journal : Leukemia

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis.

Authors : Massaro F, Meuleman N, Bron D, Vercruyssen M, Maerevoet M
Year : 2022
Journal : Cancers (Basel)

Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice.

Authors : Delforge M, Vekemans MC, Depaus J, Meuleman N, Van de Velde A, Vande Broek I, Vandervennet S, Van Hoorenbeeck S, Moorkens E, Strens D, Diels J, Ghilotti F, Haefliger B, Dalhuisen S, Deraedt W, Anguille S
Year : 2022
Journal : Hemasphere

More publications »